NASDAQ:VVUS - VIVUS Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.73 -0.06 (-7.59 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$0.79
Today's Range$0.73 - $0.79
52-Week Range$0.33 - $1.32
Volume799,200 shs
Average Volume1.04 million shs
Market Capitalization$85.26 million
P/E Ratio-2.62
Dividend YieldN/A
Beta0.83
VIVUS logoVIVUS, Inc., a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also involved in developing Qsymia, which has been completed Phase II studies for the treatment of various diseases, including obstructive sleep apnea and diabetes, nonalcoholic steatohepatitis and fatty liver disease, hyperlipidemia, and hypertension, as well as Tacrolimus that has been completed Phase IIa studies for the treatment of pulmonary arterial hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin Chemie AG to commercialize and promote STENDRA. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:VVUS
CUSIP92855110
Phone650-934-5200

Debt

Debt-to-Equity Ratio-12.06
Current Ratio8.67
Quick Ratio7.94

Price-To-Earnings

Trailing P/E Ratio-2.62
Forward P/E Ratio-1.70
P/E GrowthN/A

Sales & Book Value

Annual Sales$65.37 million
Price / Sales1.18
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-8.11

Profitability

EPS (Most Recent Fiscal Year)($0.29)
Net Income$-30,510,000.00
Net Margins-79.80%
Return on Equity-843.43%
Return on Assets-15.08%

Miscellaneous

Employees52
Outstanding Shares106,050,000

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.01. The biopharmaceutical company earned $11.90 million during the quarter. VIVUS had a negative return on equity of 843.43% and a negative net margin of 79.80%. View VIVUS's Earnings History.

When is VIVUS's next earnings date?

VIVUS is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for VIVUS.

Who are some of VIVUS's key competitors?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:
  • Mr. Mark K. Oki, CFO & Chief Accounting Officer (Age 49)
  • Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 53)
  • Dr. Santosh T. Varghese, Chief Medical Officer (Age 48)
  • Mr. Allan J. Lee Shaw, Consultant & Director (Age 54)
  • Mr. Seth H. Z. Fischer, Strategic Adviser (Age 62)

Has VIVUS been receiving favorable news coverage?

Media coverage about VVUS stock has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. VIVUS earned a media sentiment score of 0.04 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of VIVUS?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VVUS stock can currently be purchased for approximately $0.73.

How big of a company is VIVUS?

VIVUS has a market capitalization of $85.26 million and generates $65.37 million in revenue each year. The biopharmaceutical company earns $-30,510,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. VIVUS employs 52 workers across the globe.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]


MarketBeat Community Rating for VIVUS (VVUS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  581
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.